BiotechTube
HbO2 Therapeutics

HbO2 Therapeutics

San Diego, United States· Est.
hbo2therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

HbO2 Therapeutics is a private, commercial-stage biotech focused on oxygen-carrying therapeutics. Its core asset, Hemopure, is an approved human HBOC in select markets and is being developed for new applications in organ transplantation and severe anemia where blood transfusion is not an option. The company leverages over 25 years of R&D, a substantial preclinical and clinical data package, and an approved veterinary product to fund and de-risk its human therapeutic development.

AnemiaOrgan TransplantationIschemia/HypoxiaVeterinary Medicine

Technology Platform

Hemoglobin-based oxygen carriers (HBOCs) using purified, polymerized bovine hemoglobin to create cell-free, universally compatible oxygen therapeutics.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The organ transplantation application represents a major near-term opportunity to address the critical shortage of viable donor organs and reduce discard rates, potentially creating a new standard of care in organ preservation.
The ongoing need for blood transfusion alternatives in niche populations (e.g., patients who refuse blood, in remote locations) provides a stable, addressable human market.

Risk Factors

Key risks include the historical safety challenges associated with the HBOC class, which could impede new regulatory approvals.
The company also faces commercial risks in expanding beyond niche anemia indications and operational risks associated with consolidating manufacturing to a single site.

Competitive Landscape

The competitive landscape for human HBOCs is sparse due to historical clinical failures, leaving HbO2 as one of the few companies with an approved product (in some markets). In organ preservation, it competes with static cold storage and emerging machine perfusion technologies. In veterinary anemia, Oxyglobin faces competition from animal blood banks and other supportive care products.

More companies in Biologics / Biosimilars →More companies in United States →